Valsartan

Valsartan (CAS 137862-53-4), also known as VAL489, is an angiotensin II receptor antagonist used as an active pharmaceutical ingredient in the treatment of hypertension and heart failure. It functions by selectively blocking the AT1 receptor subtype.

This makes it a core API in cardiovascular drug formulations worldwide. Valsartan is the primary active ingredient in oral solid dosage forms, such as tablets and capsules, manufactured for antihypertensive therapy.

It is often utilized in combination products alongside hydrochlorothiazide or amlodipine. Pharmaceutical manufacturers source it as a key API for generic drug production, where it undergoes formulation development and bioequivalence testing.

The material is also essential for regulatory filing and clinical trials. Contract research organizations and formulation labs procure it for analytical reference standards and method development work to ensure product quality.

In some specialty contexts, it is evaluated within peptide-adjacent research programs targeting cardiovascular peptide pathways. Valsartan is supplied as a white to off-white crystalline powder for industrial use.

It is available in pharmaceutical-grade specifications conforming to USP, Ph.Eur. (EP), and BP monographs, supporting GMP-compliant manufacturing processes across various global regions.

Quantities range from research-scale lots to multi-kilogram commercial batches. Documentation packages including CoA, DMF references, and impurity profiles are available on request to support your compliance needs.